medigraphic.com

2008, Number 6

<< Back Next >>

Rev Med Inst Mex Seguro Soc 2008; 46 (6)

Candiduria in Type 2 Diabetes Mellitus Patients and its Clinical Significance. Candida spp. Antifungal Susceptibility

Manzano-Gayosso P, Hernández-Hernández F, Zavala-Velásquez N, Méndez-Tovar LJ, Naquid-Narváez JM, Torres-Rodríguez JM, López-Martínez R

Language: Spanish
References: 34
Page: 603-610
PDF size: 120.79 Kb.


ABSTRACT

Background: Candida is frequently seen in urinalysis studies in patients with diabetes mellitus. The objective was to determine the presence and clinical significance of candiduria, and to identify the different isolated Candida species and their in vitro susceptibility pattern to different antifungal agents by means of the broth microdilution method.
Methods: we studied the urine from 50 type 2 diabetes mellitus (DMT2) patients. 24 patients had controlled DMT2 and 26 noncontrolled DMT2.
Results: twenty-three Candida spp. positive cultures were obtained, of which 17 were obtained from the non-controlled DMT2 patients; 30.7 % of the isolates were caused by Candida infection. The main isolated species were C. glabrata (48 %) and C. albicans (35 %). Itraconazole, amphotericine B, and ketoconazole showed less antifungal activity in C. glabrata isolates, whereas fluconazole and voriconazole displayed higher antifungal activity.
Conclusions: it is important to search routinely for yeast in the urine of DMT2 patients to detect candidiasis, and to perform antifungal susceptibility tests to Candida isolates in order to establish antifungal therapy for these patients.


REFERENCES

  1. Kauffman CA. Candiduria: diagnostic and treatment conundrums. Curr Treat Opt Infect Dis 2002; 4:513-519.

  2. Sobel JD. Controversies in the diagnosis of candiduria: what is the critical colony count? Curr Treat Opt Infect Dis 2002;4:81-83.

  3. Kauffman CA. Candiduria. Clin Infect Dis 2005; 41:S371-S376.

  4. Febré N, Silva V, Medeiros EA, Wey SB, Colombo AL, Fischman O. Microbiological characteristics of yeasts isolated from urinary tracts of intensive care unit patients undergoing urinary catheterization. J Clin Microbiol 1999;37:1584-1586.

  5. Harris AD, Castro J, Sheppard DC, Carmeli Y, Samore MH. Risk factors for nosocomial candiduria due to Candida glabrata and Candida albicans. Clin Infect Dis 1999;29:926-928.

  6. Krcmery S, Dubrava M, Krcmery V Jr. Fungal urinary tract infections in patients at risk. Int J Antimicrob Agents 1999;11:289-291.

  7. Kauffman CA, Vázquez JA, Sobel JD, Gallis HA, McKinsey DS, Karchmer AW, Sugar AM, Sharkey PK, Wise GJ, Mangi R, Mosher A, Lee JY, Dismukes WE. Prospective multicenter surveillance study of funguria in hospitalized patients: The National Institute for Allergy and Infectious Disease (NIAID) Mycoses Study Group. Clin Infect Dis 2000;30:14-18.

  8. Gilbert JW, Silver DA. Fungal infections of the genitourinary system. J Urol 1993;149:1377-1388.

  9. Kobayashi CC, de Fernandes OF, Miranda KC, de Sousa ED, Silva M do R. Candiduria in hospital patients: A study prospective. Mycopathologia 2004; 158:49-52.

  10. Emori TG, Banerjee SN, Culver DH, Gaynes RP, Horan TC, Edwards JR, Jarvis WR, Tolson JS, Henderson TS, Martone WJ, et al. Nosocomial infections in elderly patients in the United States, 1986-1990, National Nosocomial Infections Surveillance System. Am J Med 1991;91(3B):289S-293S.

  11. Maenza JR, Merz WG, Romagnoli MJ, Keruly JC, Moore RD, Gallant JE. Infection due to fluconazole- resistant Candida in patients with AIDS: prevalence and microbiology. Clin Infect Dis 1997; 24:28-34.

  12. Odds FC. Resistance of yeasts to azole derivative antifungals. J Antimicrob Chemother 1993;31: 463-471.

  13. Vanden Bossche H, Marichal P, Odds FC, Le Jeune L, Coene MC. Characterization of an azoleresistant Candida glabrata isolate. Antimicrob Agents Chemother 1992;36:2602-2610.

  14. Safdar A, van Rhee F, Henslee-Downey JP, Singhal S, Mehta J. Candida glabrata and Candida krusei fungemia after high-risk allogeneic marrow transplantation: no adverse effect of low-dose fluconazole prophylaxis on incidence and outcome. Bone Marrow Transplant 2001;28: 873-878.

  15. Tinoco JC, Hernández-Ruiz E, Salvador-Moysen J, Rivera-Morales I. Infecciones nosocomiales de vías urinarias en un hospital de segundo nivel. Salud Publica Mex 1994;36:17-21.

  16. American Diabetes Association. Physician’s guide to non-insulin-dependent (type II) diabetes: diagnosis and treatment. Second edition. Alexandria, VA: American Diabetes Association; 1989.

  17. De Oliveira RD, Maffei CM, Martinez R. Infecção urinária hospitalar por levaduras do género Candida. Rev Assoc Med Bras 2001;47:231-235.

  18. Goldberg PK, Kozinn PJ, Wise GJ, Nouri N, Brooks RB. Incidence and significance of candiduria. JAMA 1979;241:582-584.

  19. Odds FC, Bernaerts R. CHRO Magar Candida, a new differential isolation medium for presumptive identification of clinically important Candida species. J Clin Microbiol 1994;32:1923-1929.

  20. Staib P, Morschhaüser J. Chlamydospore formation on Staib agar as a species-specific characteristic of Candida dubliniensis. Mycoses 1999;42: 521-524.

  21. Staib F, Arasteh K. Chlamydospore formation on Staib agar. Observations made before Candida dubliniensis was described. Mycoses 2001;44:23-27.

  22. Sullivan D, Coleman D. Candida dubliniensis: Characteristics and identification. J Clin Microbiol 1998;36:329-334.

  23. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved Standard M27-A2. Wayne, PA: National Committee for Clinical Laboratory Standards; 2002.

  24. Rex JH, Pfaller MA, Walsh TJ, Chaturvedi V, Espinel-Ingroff A, Ghannoum MA, et al. Antifungal susceptibility testing: practical aspects and current challenges. Clin Microbiol Rev 2001;14: 643-658.

  25. Fisher JF, Chew WH, Shadomy S, Duma RJ, Mayhall CG, House WC. Urinary tract infections due to Candida albicans. Rev Infect Dis 1982;4: 1107-1118.

  26. Torres-Rodríguez JM, Morera Y, López O. Candida glabrata. Un patógeno emergente. Boletín de Control de Calidad SEIMC 2000;12:39-43.

  27. Lundstrom T, Sobel J. Nosocomial candiduria: a review. Clin Infect Dis 2001;32:1602-1607.

  28. Antoniadou A, Torres HA, Lewis RE, Thornby J, Bodey GP, Terrand JP, Han XY, Rolston KV, Safdar A, Raad II, Kontoyiannis DP. Candidemia in a tertiary care cancer center: in vitro susceptibility and its association with outcome of initial antifungal therapy. Medicine 2003;82: 309-321.

  29. Safdar A, Chaturvedi V, Cross EW, Park S, Bernard E, Armstrong D, Perlin DS. Prospective study of Candida species in patients at a comprehensive cancer center. Antimicrob Agents Chemother 2001;45:2129-2133.

  30. Mathema B, Cross E, Dun E, Park S, Bedell J, Slade B, Williams M, Riley L, Chaturvedi V, Perlin DS. Prevalence of vaginal colonization by drug-resistant Candida species in college-age woman with previous exposure to over-the-counter azole antifungals. Clin Infect Dis 2001;33:E23-E27.

  31. Baran J Jr, Klauber E, Barczak J, Riederer K, Khatib R. Trends in antifungal susceptibility among Candida spp. Urinary isolates from 1994 and 1998. J Clin Microbiol 2000;38:870-871.

  32. Boschman CR, Bodnar UR, Tornatore MA, Obias AA, Noskin GA, Englund K, et al. Thirteen-year evolution of azole resistance in yeast isolates and prevalence of resistant strains carried by cancer patients at a large medical center. Antimicrob Agents Chemother 1998; 42:734-738.

  33. Pfaller MA, Messer SA, Hollis RJ, Jones RN, Diekema DJ. In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6970 clinical isolates of Candida spp. Antimicrob Agents Chemother 2002;46:1723-1727.

  34. Pappas PG, Rex JH, Sobel JD, et al. Guidelines for treatment of candidiasis. Clin Infect Dis 2004; 38:161-189.




2020     |     www.medigraphic.com